Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
US Army
Mallinckrodt
Argus Health
McKinsey

Generated: March 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RECLAST

« Back to Dashboard

Clinical Trials for Reclast

Trial ID Title Status Sponsor Phase Summary
NCT00171964 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed Novartis Pharmaceuticals Phase 4 It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and analgesic consumption.
NCT00439647 Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis Completed Novartis Pharmaceuticals Phase 3 This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed National Institute on Aging (NIA) N/A This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed National Institutes of Health (NIH) N/A This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed University of Pittsburgh N/A This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
NCT00668200 Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® Completed Novartis Pharmaceuticals Phase 4 This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in patients with Paget's disease of bone.
NCT00740129 Re-treatment of Patients With Paget's Disease Using Zoledronic Acid Completed Novartis Pharmaceuticals Phase 4 The purpose of this study is to demonstrate that patients with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5mg infusion of zoledronic acid.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Reclast

Condition Name

Condition Name for Reclast
Intervention Trials
Paget's Disease of the Bone 2
Osteoporosis 2
Bone Loss 2
Stage II Pancreatic Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Reclast
Intervention Trials
Osteoporosis 5
Bone Diseases, Metabolic 2
Osteitis Deformans 2
Bone Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Reclast

Trials by Country

Trials by Country for Reclast
Location Trials
United States 12
Belgium 2
Germany 2
Spain 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Reclast
Location Trials
Georgia 2
Pennsylvania 2
Nebraska 1
New Jersey 1
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Reclast

Clinical Trial Phase

Clinical Trial Phase for Reclast
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Reclast
Clinical Trial Phase Trials
Completed 7
Recruiting 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Reclast

Sponsor Name

Sponsor Name for Reclast
Sponsor Trials
Novartis Pharmaceuticals 5
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 1
Chi Lin, MD 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Reclast
Sponsor Trials
Industry 7
Other 4
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Moodys
Harvard Business School
Merck
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.